埃达拉德克斯本醇通过NF-κB/NLRP3信号通路缓解大脑缺血-再输液损伤
Guanghong Shen1, Chengjian Lou2, Qunfeng Li3
1School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
埃达拉德克斯本 (C.EDA) 能保护大鼠中风后的炎症性损伤. 它通过阻断NLRP3炎症酶和通过NF-κB通路调节微质分极作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 炎症研究 炎症研究
背景情况:
- 缺血-再输液 (I/R) 损伤导致显著的炎症损伤,限制了中风治疗的有效性.
- 埃达拉德克斯本醇 (C.EDA) 已显示出在脑出血后减少炎症的潜力,但其精确的抗炎机制尚不清楚.
研究的目的:
- 在大脑I/R损伤的老鼠模型中研究C.EDA的神经保护作用.
- 阐明C.EDA的潜在抗炎机制,重点关注NF-κB/NLRP3炎症酶通路和微质分离.
主要方法:
- 在Sprague-Dawley大鼠中建立了一个中脑动脉封闭/再输 (I/R) 模型.
- 评估神经功能,心脏病发作量和血脑屏障的完整性.
- 利用激光斑点成像,TTC染色,埃文的蓝色染色,免疫光学和西部涂抹来分析分子通路和细胞反应.
主要成果:
- 在I/R大鼠中,C.EDA治疗显著改善了神经学评分,减少了脑梗塞体积,并保持了血脑屏障的完整性.
- C.EDA降低了iNOS,NLRP3和NF-κB蛋白的表达,同时增加了Arg1水平.
- 西部斑点分析证实NF-κB/NLRP3炎症体信号通路的激活减少.
结论:
- 在大鼠模型中,C.EDA显示出对I/R损伤的显著神经保护.
- 该机制涉及抑制NLRP3炎症酶激活,并通过NF-κB信号通路调节M1/M2微质极化.
更多相关视频
14:05Generation of Hook Ischemia-Reperfusion Model using a Three-Day Developing Chick Embryo
Published on: February 19, 2022
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
相关概念视频
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Nitric Oxide Signaling Pathway
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
